At 70 years old, Johnson & Johnson isn’t slowing down. The company, maker of Tylenol, Neutrogena, and other household brands, reported $13.8 billion in 2013 profits, a gain of more than 27% year-over-year. The pharmaceutical business had an exceptional year with 12% annual operational growth, making J&J the fastest growing top 10 pharmaceutical company in the U.S., Europe and Japan. CEO Alex Gorsky plans to sustain that growth through continued investment in research and development. Last year alone, the company allocated over $8 billion, or 11% of sales, to support R&D. Recent research efforts are paying off: About 25% of sales came from products J&J brought to market in the past five years.